

DAFTAR PUSTAKA

1. Center for Disease Control and Prevention. Basic Information About Breast Cancer. Center for Disease Control and Prevention. 2019. p. 1–2.
2. Pangribowo S. Beban Kanker di Indonesia. Pus Data dan Inf Kementerian Kesehat RI. 2019;1–16.
3. Profil Kesehatan Indonesia Tahun 2015. Jakarta: Kementerian Kesehatan RI. 2016.
4. Rahmatya A, Khambri D, Mulyani H. Hubungan usia dengan gambaran klinikopatologi kanker payudara di bagian bedah RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas. 2015;4(2):478-84.
5. Profil Kesehatan Indonesia Tahun 2017. Jakarta: Kementerian Kesehatan RI. 2018.
6. Dai X, et al. Breast cancer intrinsic subtype classification , clinical use and future trends. 2015;2929–43.
7. Kondov B et al. Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. Open Access Maced J Med Sci. 2018;1–16.
8. Mohammed AA. Prognostic parameter differences in breast cancer patients between luminal A and luminal B types after application of the new classification according to Ki67 score. International Journal of Surgery Open. 2021 Jul 1;34.
9. Pellegrino B, Hlavata Z, Migali C, de Silva P, Aiello M, Willard-Gallo K, et al. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Vol. 25, Molecular Diagnosis and Therapy. Adis; 2021. p. 409–24.
10. Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome [Internet]. Vol. 7. 2016. Available from: www.impactjournals.com/oncotarget
11. Serrano-Gomez SJ, Sanabria-Salas MC, Hernández-Suarez G, García O, Silva C, Romero A, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women.

- Carcinogenesis. 2016 Jul 1;37(7):669–76.
- 12. Paramita S, Raharjo EN, Niasari M, Azizah F, Hanifah NA. Luminal B is the most common intrinsic molecular subtypes of invasive ductal breast carcinoma patients in East Kalimantan, Indonesia. *Asian Pacific Journal of Cancer Prevention*. 2019;20(8):2247–52.
 - 13. Chen BF, Tsai YF, Huang CC, Hsu CY, Lien PJ, Wang YL, et al. Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan. *J Chin Med Assoc*. 2022 Feb 1;85(2):190–7.
 - 14. Ho PJ, Ow SGW, Sim Y, Liu J, Lim SH, Tan EY, et al. Impact of deviation from guideline recommended treatment on breast cancer survival in Asia. *Scientific Reports*. 2020 Dec 1;10(1).
 - 15. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst*. 2009 May;101(10):736–50.
 - 16. Kim KH, Chae BJ, Song BJ, Jung SS. Ki-67 and p53 as Prognostic Factors for Luminal Type Breast Cancer. *Journal of Breast Disease*. 2013 Nov 19;1(1):21–7.
 - 17. Lakhani S. Molecular Testing for Estrogen Receptor, Progesterone Receptor, and HER2. 4th ed. 2012.
 - 18. Perhimpunan Ahli Bedah Onkologi Indonesia. Panduan Penatalaksanaan Kanker 2020. II. In: Djoko H, Haryono S, Arief HW, editors. 2020.
 - 19. Zubair M, Wang S, Ali N. Advanced Approaches to Breast Cancer Classification and Diagnosis. *Frontiers in Pharmacology*. 2021 Feb 26;11.
 - 20. Szymczek A, Lone A, Akbari MR. Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. *Clin Genet*. 2021;99(5):613–37.
 - 21. Kobayashi N, Hikichi M, Ushimado K, Sugioka A, Kiriyama Y, Kuroda M, et al. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and

- their impact on survival. *Clin Transl Oncol.* 2017;19(10):1232–40.
22. Zaha DC. Significance of immunohistochemistry in breast cancer. *World Journal of Clinical Oncology.* 2014;5(3):382.
23. Robinson M, Atmakusumah TD, Irawan C, Shatri H. Immunohistochemistry Profile of Breast Cancer Patients that Get Anthracycline – Based Chemotherapy in RSUD Kota Bogor. *J Penyakit Dalam Indones.* 2019;6(4):173–7.
24. Warjianto W, Soewoto W, Alifianto U, Wujoso H. Hubungan Reseptor Estrogen, Reseptor Progesteron dan Ekspresi Her-2/Neu Dengan Grading Histopatologi pada Pasien Kanker Payudara di RSUD dr. Moewardi Surakarta. *Smart Medical Journal.* 2020 Dec 28;3(2):96.
25. Lakhani S, Marc J, Jocelyn J, Thomas J, Peter P LM. The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, 59 Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2. *J Clin Oncol.* 2017;10–8.
26. Colditz G, Chia KS, Wilson R, Britton P, Morrow M, Rutgers E, et al. Invasive breast carcinoma: introduction and general features. In: Lakhani SR EISSTPVM, editor. WHO classification of tumours of the breast. 2012. p. 14–7.
27. Sakhdari A HLCE. Molecular pathology of HER family of oncogenesis in breast cancer: HER-2 evaluation and role in targeted therapy. In: Khan A EIHCERED, editor. Precision molecular pathology of breast cancer. New York: Springer; 2015. p. 119–36.
28. Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers:Overexpression and Therapeutic Implications. *Molecular Biology International.* 2014;1–9.
29. Simon R, Nocito A, Hübscher T, et al. Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer. *JNCI.* 2001;93(15):1141–6.
30. E.C. I. Ki-67 is Prognostic Parameter in Breast Cancer Patients: results of a large population-based cohort of a cancer registry. *Breast Cancer Treat.* 2012;539–52.

31. Wellings E, Vassiliades L, Abdalla R. Breast Cancer Screening for High-Risk Patients of Different Ages and Risk - Which Modality Is Most Effective? *Cureus*. 2016 Dec 28;
32. Feng Y, Spezia M, Huang S, Yuan C, Zrng Z, Zhang L. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes & Disease*. 2018;5:77–106.
33. Dieci MV, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S, et al. Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. *Clinical Cancer Research*. 2022 Jan 15;28(2):308–17.
34. Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al. Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. Vol. 32, *Journal of Clinical Oncology*. American Society of Clinical Oncology; 2014. p. 2794–803.
35. Park C, Park K, Kim J, Sin Y, Park I, Cho H, et al. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer. *World Journal of Surgical Oncology*. 2016 Sep 13;14(1).
36. Tang LC, Jin X, Yang HY, He M, Chang H, Shao ZM, et al. Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China. *BMC Cancer*. 2015 Mar 29;15(1).
37. Kim H, Lee SB, Kim J, Chung IY, Kim HJ, Ko BS, et al. Improvement of survival in Korean breast cancer patients over a 14-year period: A largescale single-center study. *PLoS ONE*. 2022 Mar 1;17(3 March).
38. Ding N hua, Liu C fan, Hu C, Yuan J qi, Liao W hua, Xiao Z. Prognostic Factors for Luminal B-like Breast Cancer. *Current Medical Science*. 2019 Jun 1;39(3):396–402.
39. Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, et al. Histological grade provides significant prognostic information in addition to breast cancer subtypes

- defined according to St Gallen 2013. *Acta Oncologica*. 2017 Jan 2;56(1):68–74.
40. Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. *World Journal of Surgical Oncology*. 2018 Jan 2;16(1).
41. Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, et al. Outcome of special types of luminal breast cancer. *Annals of Oncology*. 2012 Jun 1;23(6):1428–36.
42. Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. *Annals of Oncology*. 2014 May 1;25(5):1004–11.
43. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. *Annals of Oncology*. 2013;24(3):632–9.
44. Sahin S, Erdem GU, Karatas F, Aytekin A, Sever AR, Ozisik Y, et al. The association between body mass index and immunohistochemical subtypes in breast cancer. *The Breast*. 2017 Apr;32:227–36.
45. San TH, Fujisawa M, Fushimi S, Soe L, Min NW, Yoshimura T, et al. Molecular subtypes of breast cancers from Myanmar women: A study of 91 cases at two pathology centers. *Asian Pacific Journal of Cancer Prevention*. 2017 Jun 1;18(6):1617–21.
46. el Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, et al. Retraction: Luminal B tumors are the most frequent molecular subtype in breast cancer of north african women: An immunohistochemical profile study from morocco. *Diagn Pathol*. 2013 Aug 14;8(1).

47. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. Vol. 5, World Journal of Clinical Oncology. Baishideng Publishing Group Co., Limited; 2014. p. 412–24.
48. Klebe M, Fremd C, Kriegsmann ; Mark, Kriegsmann K, Albrecht T, Thewes V, et al. Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer [Internet]. 2020. Available from: <https://doi.org/10.>
49. Zhang L, Huang Y, Feng Z, Wang X, Li H, Song F, et al. Comparison of breast cancer risk factors among molecular subtypes: A case-only study. *Cancer Med.* 2019 Apr 14;8(4):1882–92.
50. Cheng SA, Liang LZ, Liang QL, Huang ZY, Peng XX, Hong XC, et al. Breast cancer laterality and molecular subtype likely share a common risk factor. *Cancer Manag Res.* 2018 Nov;Volume 10:6549–54.
51. Mills M, Liveringham C, Lee F, Nanda RH, Ahmed KA, Washington IR, et al. The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes. *J Geriatr Oncol.* 2021 Mar 1;12(2):219–26.
52. Creighton CJ. The molecular profile of luminal B breast cancer. Vol. 6, *Biologics: Targets and Therapy.* 2012. p. 289–97.
53. Sali AP, Sharma N, Verma A, Beke A, Shet T, Patil A, et al. Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance. *Clin Breast Cancer.* 2020 Oct;20(5):382–9.
54. Jääskeläinen A, Roininen N, Karihtala P, Jukkola A. High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study. *Front Oncol.* 2020 Aug 14;10.

55. Erber R, Angeloni M, Stöhr R, Lux MP, Ulbrich-Gebauer D, Pelz E, et al. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test—Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. *Int J Mol Sci.* 2022 Aug 1;23(15).
56. de Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A, et al. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. *Br J Cancer.* 2022 Jun 1;126(12):1715–24.
57. Liu Z, Sahli Z, Wang Y, Wolff AC, Cope LM, Umbricht CB. Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study. *Breast Cancer Res Treat.* 2018 Dec 17;172(3):689–702.
58. Lian W, Fu F, Lin Y, Lu M, Chen B, Yang P, et al. The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer. *Sci Rep.* 2017 Dec 1;7(1).
59. Gómez-Acebo I, Dierssen-Sotos T, Palazuelos-Calderón C, Pérez-Gómez B, Amiano P, Guevara M, et al. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. *Breast Cancer Res Treat.* 2020 Jun 1;181(3):667–78.
60. Karakolevska-Ilova M, Zdravkovska M, Jasar D, Petrusovska G, Simeonovska-Joveva E. Can estrogen receptor, progesterone receptor, and proliferative index be considered as isolated prognostic factors of overall survival in early luminal breast cancer? Open Access Maced J Med Sci. 2021 Dec 26;9:1313–22.
61. Rajc J, Fröhlich I, Mrčela M, Tomaš I, Flam J. Prognostic impact of low estrogen and progesterone positivity in luminal b (HER2 negative) breast cancer. *Acta Clin Croat.* 2018;57(3):425–33.

62. Utsumi T, Kobayashi N, Hikichi M, Ushimado K, Kuroda M. Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and-negative subtypes. Available from: <https://doi.org/10.20407/fmj.2020-023>
63. Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airolidi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. *Breast Cancer Res Treat.* 2016 Jun 1;157(2):363–71.
64. Thangarajah F, Enninga I, Malter W, Hamacher S, Markiefka B, Richters L, et al. A retrospective analysis of Ki-67 index and its prognostic significance in over 800 primary breast cancer cases. *Anticancer Res.* 2017 Apr 1;37(4):1957–64.
65. Wilson BE, Desnoyers A, Al>Showbaki L, Nadler MB, Amir E. A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time. *Sci Rep.* 2022 Dec 1;12(1).
66. Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. *The Lancet.* 2012 Feb 4;379(9814):432–44.
67. Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Vol. 6, *Breast Cancer: Basic and Clinical Research.* 2012. p. 159–71.
- Rabinovich I, de Noronha L, Sebastião APM, Lima RS, Urban CA, Schunemann E, et al. HER2-expressing breast tumors are associated with breast cancer stem-cell phenotype CD44 + /CD24 -. *J Bras Patol Med Lab.* 2018 Sep 1;54(5):310–8.